CASI Pharmaceuticals (CASIF) Total Debt (2021 - 2025)

CASI Pharmaceuticals has reported Total Debt for 5 years, with the latest figure at $19.2 million in Q4 2025.

• For the quarter ending Q4 2025, Total Debt rose 4.38% year-over-year to $19.2 million; the trailing twelve-month figure through Dec 2025 stood at $19.2 million (up 4.38% YoY), and the FY2025 full-year result was $19.2 million, up 4.38% from the prior year.
• Total Debt for Q4 2025 stood at $19.2 million, up from $18.4 million in the prior quarter.
• The five-year high for Total Debt was $18.9 billion in Q4 2023, with the low at $11.8 million in Q4 2022.
• Historically, Total Debt has averaged $5.3 billion across 5 years, with a median of $18.6 million in 2024.
• Annual changes were most pronounced in 2023 — Total Debt soared 159742.65% — and 2024, when it plunged 99.9%.
• CASI Pharmaceuticals' Total Debt stood at $13.2 million in 2021, then retreated by 10.58% to $11.8 million in 2022, then soared by 159742.65% to $18.9 billion in 2023, then sank by 99.9% to $18.4 million in 2024, then climbed by 4.38% to $19.2 million in 2025.
• The last three Total Debt figures came in at $19.2 million (Q4 2025), $18.4 million (Q4 2024), and $18.5 billion (Q2 2024), per Business Quant data.